<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01313897</url>
  </required_header>
  <id_info>
    <org_study_id>114344</org_study_id>
    <secondary_id>IND 14560</secondary_id>
    <nct_id>NCT01313897</nct_id>
  </id_info>
  <brief_title>UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma</brief_title>
  <acronym>NK2010-35</acronym>
  <official_title>UARK 2010-35, A Phase II Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the therapeutic efficacy of the exp-NK cell therapy
      in research participants with relapsed high risk MM [defined as gene expression profile (GEP)
      70 gene score ≥0.66 and/or metaphase chromosomal abnormalities and/or high LDH ≥ 360U/L] by
      establishing the (near) complete response rate. Response rate will be compared to case
      matched historical controls (patients who relapsed on Total Therapy 2 or 3 with high-risk MM
      defined as above). Disease-free survival and overall survival will be captured but are not
      primary or secondary endpoints.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of auto-exp-NK cells in this protocol makes therapy available to all refractory high
      risk MM patients, 2/3 of whom would otherwise not have a suitable haploidentical donor. We
      have shown that NK cells can be expanded both from newly diagnosed high risk MM patients and
      from refractory, previously heavily treated patients, the very individuals in need of novel
      therapies such as exp-NK cell infusions. Furthermore, we observed that exp-NK cells have the
      ability to kill auto-MM cells in vitro compared to no killing with resting auto-NK cells.
      This may be due to the elevated activation state of exp-NK cells, which allows them to
      overcome otherwise dominant inhibitory signaling. The incorporation of the proteasome
      inhibitor bortezomib, which down regulates the principal NK cell inhibitory ligands on MM
      cells should further increase the efficacy of auto-exp-NK cells. Because there is no risk for
      GvHD, CD3+ T cell depletion will not be necessary for auto-exp-NK cell products.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic Efficacy</measure>
    <time_frame>180 days</time_frame>
    <description>Number of participants with an objective response of Partial Response (PR) or better according to European Society for Blood and Marrow Transplantation (EBMT) criteria within 180 days post Expanded Natural Killer Cell Infusion. The minimum criteria to meet the EBMT definition of PR or better included: &gt;= 50% reduction in size of soft tissue plasmacytomas (if assessed); AND &gt;= 50% reduction in plasma cells in bone marrow biopsy (if biopsy was performed and if &gt;= 30% plasma cells at baseline); AND &gt;=50% reduction in serum M protein and reduction in urine M protein &gt;= 90% or to 200 mg/24hr OR &gt;= 50% decrease in the difference between involved and uninvolved serum free light chain levels (if serum M protein &lt; 1 g/dL, urine &lt; 200 mg/24 hrs, and an involved serum free light chain level &gt;= 10 mg/dL at baseline).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Velcade for Anti-MM therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day(s) -9,-6,-2 3 doses of Bortezomib at 1.0 mg/m2, i.v.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>bortezomib to be given days -9, -6, and -2 at 1.0mg/m2, i.v.</description>
    <arm_group_label>Velcade for Anti-MM therapy</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient (Recipient of NK Cells) Inclusion Criteria

          -  Relapsed patients must have high risk disease as defined by GEP risk score of ≥ 0.66
             or metaphase cytogenetic abnormalities or LDH ≥ 360 U/L (Rule out hemolysis, infection
             and contact PI for clarification if any doubt) Patients must have had at least 1 line
             of prior chemotherapy and/or have relapsed after auto- PBSCT.

          -  For subjects who have had a prior transplant, ≥2 months must have relapsed after the
             last transplant prior to enrollment.

          -  Zubrod ≤ 2, unless solely due to symptoms of MM-related (bone) disease.

          -  Patients must have a platelet count of ≥ 50,000/µL within 35 days of registration,
             unless lower levels are explained by extensive bone marrow plasmacytosis or extensive
             prior therapy.

          -  Patients must be at least 18 years of age and not older than 75 years of age at the
             time of registration.

          -  Participants must have preserved renal function as defined by a serum creatinine level
             of ≤ 3 mg/dL within 35 days of registration.

          -  Participants must have an ejection fraction by ECHO or MUGA scan ≥ 40% within 90 days
             prior to registration.

          -  Patients must have adequate pulmonary function studies &gt; 50% of predicted on
             mechanical aspects (FEV1, FVC, etc) and diffusion capacity (DLCO) &gt; 50% of predicted
             within 90 days prior to registration. If the patient is unable to complete pulmonary
             function tests due to MM related pain or condition, exception may be granted if the
             principal investigator documents that the patient is a candidate for high dose
             therapy.

          -  Patients must have signed an IRB-approved informed consent and HIPAA authorization
             form.

          -  Either a haploidentical family donor fit to undergo leukapheresis is available or the
             recipient is fit to undergo leukapheresis for exp-NK cell generation (see donor
             selection).

          -  Patient (Recipient of NK Cells) Exclusion criteria

          -  History of poorly controlled hypertension, diabetes mellitus, or any other serious
             medical illness or psychiatric illness that could potentially interfere with the
             completion of treatment according to this protocol or could be considered to be an
             exclusion criterion deemed by the PI.

          -  Patients must not have prior malignancy, except for adequately treated basal cell or
             squamous cell skin cancer, in situ cervical cancer, or other cancer for which the
             patient has not received treatment for one year prior to enrollment. Other cancers
             will only be acceptable if the patient's life expectancy exceeds three years as
             determined by the PI.

          -  Pregnant or nursing women may not participate. Women of childbearing potential must
             have a negative pregnancy documented within one week of registration. Women/men of
             reproductive potential may not participate unless they have agreed to use an effective
             contraceptive method.

          -  Donor Inclusion Criteria

          -  The source of the NK cells will be either A) a family member who is HLA haploidentical
             to the recipient, or B) if a suitable haploidentical donor is not available, the
             recipient may be the source of the NK cells.

          -  HLA typing will be performed by the Arkansas Children's Hospital clinical laboratory.

          -  If the recipient expresses HLA-C group I, HLA-C group II, and Bw4 KIR ligands, then a
             KIR-ligand mismatched haploidentical donor cannot be found, and the recipient will be
             the source of the NK cells.

          -  If the recipient fails to express one or more of the primary KIR ligands (HLA-C group
             I, HLA-C group II, and Bw4) then family member donors will be HLA typed in an effort
             to find a haploidentical donor. If multiple haploidentical donors are available, KIR
             phenotyping will be performed in Dr. van Rhee's research laboratory to select a KIR
             mismatched donor whenever possible.

          -  Donor selection will be performed by the PI or one of the MD co-investigators if Dr.
             van Rhee is not available.

          -  Signed IRB approved consent and HIPAA authorization form.

          -  Donor is not HIV I/II (+).

          -  Donor is not HTLV-I/II (+).

          -  Donor is not Hepatitis B or C (+) unless positive due to previous vaccination or has
             received therapy and is negative for Hepatitis B or C by RT-PCR.

          -  Donor is a suitable candidate for insertion of apheresis catheter. Donors with unusual
             anatomy or vascular anomalies preventing insertion of a pheresis catheter will be
             rejected.

          -  Age 18 years or greater or has signed an Assent and be age ≥16 years.

          -  Donor has a negative pregnancy test by serum or urine test.

          -  In preparation for the peripheral blood mononuclear cell donation, the donor will
             undergo a detailed medical history and physical examination. Clinical studies will
             include blood chemistries (electrolytes, liver function and CRP) CBC with differential
             and platelets, PT/PTT, viral panel, EKG (age over 40 yrs), and chest x-ray (age over
             40yrs). Fitness to donate cells for NK expansion will be evaluated by a physician not
             involved in the initial assessment of the exp-NK cell recipient for enrollment onto
             the protocol.

          -  Serologic evaluation will be used to assess exposure to syphilis, West Nile Virus,
             Chagas, CMV IgG, hepatitis B, and C, HIV I and II, and HTLV I/II. An HIV-I/II[+] and
             HTLV-1/II (+) donor will be rejected on medical grounds. Donors who been vaccinated
             against hepatitis B and who have antibodies against hepatitis B surface antigen are
             allowed.

          -  Haplo-identical donor must not have prior malignancy, except for adequately treated
             basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for
             which the patient has not received treatment for one year prior to donation.

        Exclusion Criteria:

          -  Patient (Recipient of NK Cells) Exclusion criteria

          -  History of poorly controlled hypertension, diabetes mellitus, or any other serious
             medical illness or psychiatric illness that could potentially interfere with the
             completion of treatment according to this protocol or could be considered to be an
             exclusion criterion deemed by the PI.

          -  Patients must not have prior malignancy, except for adequately treated basal cell or
             squamous cell skin cancer, in situ cervical cancer, or other cancer for which the
             patient has not received treatment for one year prior to enrollment. Other cancers
             will only be acceptable if the patient's life expectancy exceeds three years as
             determined by the PI.

          -  Pregnant or nursing women may not participate. Women of childbearing potential must
             have a negative pregnancy documented within one week of registration. Women/men of
             reproductive potential may not participate unless they have agreed to use an effective
             contraceptive method.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frits van Rhee, M.D., PHD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>March 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2011</study_first_posted>
  <results_first_submitted>March 1, 2017</results_first_submitted>
  <results_first_submitted_qc>March 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2017</results_first_posted>
  <last_update_submitted>April 14, 2017</last_update_submitted>
  <last_update_submitted_qc>April 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Treatment</title>
          <description>Bortezomib (1.0 mg/m2, IV) Days -9,-6,-2 (3 doses) Mesna (30 mg/kg, IV) Days -7, -6 (2 doses) Cyclophasphamide (60 mg/kg, IV) Day -7 (1 dose) Dexamethasone (40 mg, PO) Days -6 to -3 (4 doses) Expanded Natural Killer (exp-NK) Cell Infusion Day 0 (1 dose) Aldesleukin (IL-2) (3x10^6 IU, SC) Days 0 to 12 (13 doses)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Treatment</title>
          <description>Bortezomib (1.0 mg/m2, IV) Days -9,-6,-2 (3 doses) Mesna (30 mg/kg, IV) Days -7, -6 (2 doses) Cyclophasphamide (60 mg/kg, IV) Day -7 (1 dose) Dexamethasone (40 mg, PO) Days -6 to -3 (4 doses) Expanded Natural Killer (exp-NK) Cell Infusion Day 0 (1 dose) Aldesleukin (IL-2) (3x10^6 IU, SC) Days 0 to 12 (13 doses)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Therapeutic Efficacy</title>
        <description>Number of participants with an objective response of Partial Response (PR) or better according to European Society for Blood and Marrow Transplantation (EBMT) criteria within 180 days post Expanded Natural Killer Cell Infusion. The minimum criteria to meet the EBMT definition of PR or better included: &gt;= 50% reduction in size of soft tissue plasmacytomas (if assessed); AND &gt;= 50% reduction in plasma cells in bone marrow biopsy (if biopsy was performed and if &gt;= 30% plasma cells at baseline); AND &gt;=50% reduction in serum M protein and reduction in urine M protein &gt;= 90% or to 200 mg/24hr OR &gt;= 50% decrease in the difference between involved and uninvolved serum free light chain levels (if serum M protein &lt; 1 g/dL, urine &lt; 200 mg/24 hrs, and an involved serum free light chain level &gt;= 10 mg/dL at baseline).</description>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Velcade for Anti-MM Therapy</title>
            <description>Day(s) -9,-6,-2 3 doses of Bortezomib at 1.0 mg/m2, i.v.
Bortezomib: bortezomib given days -9, -6, and -2 at 1.0mg/m2, i.v.</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Efficacy</title>
          <description>Number of participants with an objective response of Partial Response (PR) or better according to European Society for Blood and Marrow Transplantation (EBMT) criteria within 180 days post Expanded Natural Killer Cell Infusion. The minimum criteria to meet the EBMT definition of PR or better included: &gt;= 50% reduction in size of soft tissue plasmacytomas (if assessed); AND &gt;= 50% reduction in plasma cells in bone marrow biopsy (if biopsy was performed and if &gt;= 30% plasma cells at baseline); AND &gt;=50% reduction in serum M protein and reduction in urine M protein &gt;= 90% or to 200 mg/24hr OR &gt;= 50% decrease in the difference between involved and uninvolved serum free light chain levels (if serum M protein &lt; 1 g/dL, urine &lt; 200 mg/24 hrs, and an involved serum free light chain level &gt;= 10 mg/dL at baseline).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data were collected from initiation of study therapy through 180 days post expanded natural killer cell infusion.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Treatment</title>
          <description>Bortezomib (1.0 mg/m2, IV) Days -9,-6,-2 (3 doses) Mesna (30 mg/kg, IV) Days -7, -6 (2 doses) Cyclophasphamide (60 mg/kg, IV) Day -7 (1 dose) Dexamethasone (40 mg, PO) Days -6 to -3 (4 doses) Expanded Natural Killer (exp-NK) Cell Infusion Day 0 (1 dose) Aldesleukin (IL-2) (3x10^6 IU, SC) Days 0 to 12 (13 doses)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 4 Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 4 Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 4 Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Mucositis/Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Constitutional Symptoms - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Rigors/Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Grade 5 Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Infection - other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 5 Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Skin Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Anemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Anemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Anemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Blood - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Blood - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Edema - Trunk/Genital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Cardiac General - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Rigors/Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Rigors/Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Sweating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Pain: Abdomen - NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Pain - NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Alkaline Phosphatase Increase</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Bilirubin Increase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Bilirubin Increase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Bilirubin Increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 SGOT (AST) Increase</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 SGOT (AST) Increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 4 SGOT (AST) Increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 SGPT (ALT) Increase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 SGPT (ALT) Increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 SGPT (ALT) Increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 4 SGPT (ALT) Increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Bicarbonate Decrease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Bicarbonate Decrease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Bicarbonate Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 4 Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Gait/Walking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Muscle Weakness: Whole Body</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Muscle Weakness: Whole Body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Pain: Joint</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Pain: Lower Back</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Pain: Middle Back</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Pain: Upper Back</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Confusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 4 Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Memory Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Mood Alteration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Mood Alteration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Creatinine Increase</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Creatinine Increase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 3 Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Nasal/Paranasal Reactions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Pulmonary - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 1 Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Dermatology - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Dermatology - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 2 Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Grade 1 Skin Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 2 Thrombosis/Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Frits van Rhee</name_or_title>
      <organization>University of Arkansas for Medical Sciences</organization>
      <phone>501-526-6990</phone>
      <email>vanrheefrits@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

